AB Science will present its "new perspectives and ambitions" on October 14
In a press release published on October 12, 2026, the Parisian pharmaceutical company announced the holding of a web conference intended to present its strategic directions, including its "new perspectives and ambitions". The document announces this information meeting and its agenda.
Four topics on the agenda, from governance to growth drivers
AB Science detailed the themes that will be addressed during this presentation. The first focuses on a "status report 3 months after the implementation of the new governance".
The second concerns a "review of the September 2026 Sponsor inspection". The company will then present its "new perspectives and ambitions", followed by its "growth drivers in the short and medium term".
A conference in French on October 14, followed by a question and answer session
The web conference will take place on October 14, 2026, from 6 p.m. to 7:30 p.m. Paris time, or from 12 p.m. to 1:30 p.m. Eastern US time. It will be conducted in French, with a presentation support in English, and will be followed by a question and answer session.
The presentation materials, in French and English in PDF format, will be posted on the company's website at the beginning of the conference. Access is by prior registration.
Founded in 2001 and listed on Euronext Paris, AB Science is dedicated to the research, development and commercialization of protein kinase inhibitors. Its main molecule, masitinib, has been approved in veterinary medicine and is being developed in humans in oncology, neurodegenerative, inflammatory and viral diseases.
